Pfizer fights for Viagra patent

Share this article:

Still bruised from last week's Celebrex patent decision, Pfizer is back in the courts trying to keep a generic of its ED drug from hitting the markets before its patent expires in 2019, Bloomberg reports.

The company in this battle is India's Torrent Pharmaceuticals, which is seeking to tap into Pfizer's $1.88 billion business.

Bloomberg notes that Torrent is not the first generics maker that it's taken to court over Viagra, and that the company came to an agreement with Teva which would allow the Israel-based pharmaceutical company to manufacture generic Viagra in the US in 2017 “or earlier under certain circumstances.”

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.